Nuclear medicine & theranostics for molecular imaging & targeted therapy

NUCLEAR MEDICINE & THERANOSTICS FOR MOLECULAR IMAGING & TARGETED THERAPY

Dr Aviral Singh,
Clinical Head of Theranostics and Nuclear Medicine, GenesisCare
Murdoch, Western Australia &
Consultant Nuclear Medicine Physician,
Fiona Stanley Hospital, South Metropolitan Health Service &
Royal Perth Hospital, Perth, Australia

RESEARCHER PROFILE
Filmed in Perth, Australia | May 2026

Dr Aviral Singh is a globally renowned Nuclear Medicine Physician with special interest in Theranostics. He holds a Fellowship from the Royal Australasian College of Physicians (2024), specialist certificates in Nuclear Medicine and Radiation Protection from Germany (2019), an MSc in Nuclear Medicine from King’s College London (2005), and Doctor of Medicine and PG Diploma in Cardiology from Zaporozhye State Medical University, Ukraine. 

Dr Singh is based in Perth, Western Australia since 2024 and serves as the Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Australia. He is also a Consultant Nuclear Medicine Physician at Fiona Stanley and Royal Perth Hospitals, in addition to pursuing national and international consulting physician roles as Director at Infinity Theranostics. 

His prior roles include fellowships at world-leading ENETS Centres of Excellence including, Zentralklinik Bad Berka, Germany and Royal North Shore Hospital, Australia, and consultant physician positions in nuclear medicine and theranostics in Australia, Germany, and UK, with leadership in clinical research and development, and additional training in intensive care and internal medicine.

Dr Singh has co-authored 50 peer-reviewed papers, contributed a book chapter on Copper-64 radiopharmaceuticals, and holds an h-index of 30. He has delivered over 40 invited lectures for prestigious clinical societies worldwide.

Dr. Singh acts as guest editor and associate editor and peer reviewer for multiple reputed nuclear medicine journals. He is an active researcher in the field of personalised nuclear oncology and is an Investigator for several Phase 1 to 4 clinical trials in the field of Theranostics.

Source: Supplied


ORCID iD icon
https://orcid.org/0000-0002-8320-3668

Scroll to top